- Gilead's Complera approved for HIV patients already on stable drug regimens
- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
- Study: Whooping cough vaccine may not prevent infection
- Study: Pharmacist intervention improves shingles vaccine rate
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
GURGAON, India — Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.
Under the agreement, Ranbaxy said it would produce and market the following drugs in India and other developing nations after gaining necessary regulatory approval: elvitegravir, an investigational integrase inhibitor; cobicistat, an investigational antiretroviral boosting agent; and the “Quad,” a once-daily, single-tablet combination of four separate Gilead medicines. Ranbaxy and Gilead first teamed up in 2006 to market tenofovir and emtricitabine in India and many other developing nations.
“We appreciate Gilead’s initiatives for the treatment of HIV/AIDS in the developing world, through partnerships," Ranbaxy's global pharmaceutical business president Rajiv Gulati said. "We are pleased to extend our partnership with Gilead for the in-licensed new antiretrovirals that will enhance our capability to provide quality affordable medicines for the treatment of HIV/AIDS in the developing countries.”